AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
duvelisib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| phosphatidylinositol 3-kinase inhibitors, antineoplastics | 5296 | 1201438-56-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-delta and PI3K-gamma isoforms expressed in normal and malignant B-cells. Duvelisib induced growth inhibition and reduced viability in cell lines derived from malignant B-cells and in primary CLL tumor cells. Duvelisib inhibits several key cell-signaling pathways, including B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells. Additionally, duvelisib inhibits CXCL12-induced T cell migration and M-CSF and IL-4 driven M2 polarization of macrophages.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 50 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.02 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.884 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 16.634 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 26.915 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 5.297 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 10.150 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 15.430 | % | High | 1 |
| herg | hERG pIC50 | 4.629 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.399 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 38.371 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 4.650 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK1,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 55 | |||
| kinase-selectivity-class | AXL,CDK9,ERBB2,MAP2K6,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC | 10 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 51.286 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 40.087 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 86.298 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 10.010 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 67.298 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 19.560 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.010 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 13.804 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 50.520 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 9.520 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 142.233 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 19, 2021 | EMA | Verastem Europe GmbH | |
| Sept. 24, 2018 | FDA | VERASTEM INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EM04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Phosphatidylinositol-3-kinase (Pi3K) inhibitors |
Related Drugs by ATC class:
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic lymphoid leukemia, disease | indication | 92814006 | |
| Malignant lymphoma - small lymphocytic | indication | 302841002 | |
| Follicular non-Hodgkin's lymphoma | indication | 308121000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.52 | acidic |
| pKa2 | 4.74 | Basic |
| pKa3 | 4.04 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 15MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9216982 | Jan. 5, 2029 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
| 15MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9216982 | Jan. 5, 2029 | FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) |
| 25MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9216982 | Jan. 5, 2029 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
| 25MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9216982 | Jan. 5, 2029 | FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) |
| 15MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9840505 | Jan. 10, 2032 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
| 15MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9840505 | Jan. 10, 2032 | FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) |
| 25MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9840505 | Jan. 10, 2032 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
| 25MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 9840505 | Jan. 10, 2032 | FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) |
| 15MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 12213983 | April 26, 2035 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
| 25MG | COPIKTRA | SECURA | N211155 | Sept. 24, 2018 | RX | CAPSULE | ORAL | 12213983 | April 26, 2035 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | INHIBITOR | Kd | 10.64 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Kinase | INHIBITOR | Kd | 9.62 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Kinase | INHIBITOR | IC50 | 5.80 | IUPHAR | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Kinase | INHIBITOR | IC50 | 7.07 | IUPHAR | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Kinase | IC50 | 7.29 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 610V23S0JI | UNII |
| 4037879 | VANDF |
| C4079854 | UMLSCUI |
| CHEBI:131169 | CHEBI |
| CHEMBL3039502 | ChEMBL_ID |
| 50905713 | PUBCHEM_CID |
| DB11952 | DRUGBANK_ID |
| CHEMBL5315125 | ChEMBL_ID |
| D10555 | KEGG_DRUG |
| 9856 | INN_ID |
| C586691 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7795 | IUPHAR_LIGAND_ID |
| 781354007 | SNOMEDCT_US |
| 781364003 | SNOMEDCT_US |
| 289943 | MMSL |
| 34993 | MMSL |
| d08900 | MMSL |
| 017764 | NDDF |
| 2058509 | RXNORM |
| 610V23S0JI | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Copiktra | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71779-115 | CAPSULE | 15 mg | ORAL | NDA | 27 sections |
| Copiktra | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71779-125 | CAPSULE | 25 mg | ORAL | NDA | 27 sections |
| COPIKTRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73116-215 | CAPSULE | 15 mg | ORAL | NDA | 26 sections |
| COPIKTRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73116-225 | CAPSULE | 25 mg | ORAL | NDA | 26 sections |